These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 27311363)

  • 1. Reply to Weigang Yan, Zhien Zhou, Hanzhong Li's Letter to the Editor re: Jeffrey J. Tosoian, Debasish Sundi, Bruce J. Trock, et al. Pathologic Outcomes in Favorable-risk Prostate Cancer: Comparative Analysis of Men Electing Active Surveillance and Immediate Surgery. Eur Urol 2016;69:576-81.
    Tosoian JJ; Trock BJ; Ballentine Carter H; Mamawala M
    Eur Urol; 2017 Jan; 71(1):e13. PubMed ID: 27311363
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Jeffrey J. Tosoian, Debasish Sundi, Bruce J. Trock, et al. Pathologic Outcomes in Favorable-risk Prostate Cancer: Comparative Analysis of Men Electing Active Surveillance and Immediate Surgery. Eur Urol 2016;69:576-81.
    Yan W; Zhou Z; Li H
    Eur Urol; 2017 Jan; 71(1):e12. PubMed ID: 27262630
    [No Abstract]   [Full Text] [Related]  

  • 3. Reply to Yi Zhou, Weigang Yan, and Hanzhong Li's Letter to the Editor re: Eduard Baco, Erik Rud, Lars Magne Eri, et al. A Randomized Controlled Trial to Assess and Compare the Outcomes of Two-core Prostate Biopsy Guided by Fused Magnetic Resonance and Transrectal Ultrasound Images and Traditional 12-core Systematic Biopsy. Eur Urol 2016;69:149-56.
    Baco E; Rud E; Vlatkovic L
    Eur Urol; 2016 Aug; 70(2):e55. PubMed ID: 26852076
    [No Abstract]   [Full Text] [Related]  

  • 4. Reply to Zhipeng Mai, Weigang Yan, and Zhien Zhou's Letter to the Editor re: Gabriela Ilie, Ricardo Rendon, Ross Mason, et al. A Comprehensive 6-mo Prostate Cancer Patient Empowerment Program Decreases Psychological Distress Among Men Undergoing Curative Prostate Cancer Treatment: A Randomized Clinical Trial. Eur Urol 2023;83:561-70.
    Ilie G; Rutledge RDH
    Eur Urol; 2023 Aug; 84(2):e48-e49. PubMed ID: 37244817
    [No Abstract]   [Full Text] [Related]  

  • 5. Reply to Carissa E. Chu, Peter E. Lonergan, and Peter R. Carroll's Letter to the Editor re: Vasilis Stavrinides, Francesco Giganti, Bruce Trock, et al. Five-year Outcomes of Magnetic Resonance Imaging-based Active Surveillance for Prostate Cancer: A Large Cohort Study. Eur Urol 2020;78:443-51.
    Stavrinides V; Giganti F; Emberton M; Moore CM
    Eur Urol; 2020 Sep; 78(3):e112-e113. PubMed ID: 32653326
    [No Abstract]   [Full Text] [Related]  

  • 6. Reply to Jianhui Du, Yueguang Liu, and Weigang Yan's Letter to the Editor re: Gregory T. Chesnut, Emily A. Vertosick, Nicole Benfante, et al. Role of Changes in Magnetic Resonance Imaging or Clinical Stage in Evaluation of Disease Progression for Men with Prostate Cancer on Active Surveillance. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.12.009.
    Chesnut GT; Vertosick EA; Ehdaie B
    Eur Urol; 2020 Aug; 78(2):e65-e66. PubMed ID: 32386781
    [No Abstract]   [Full Text] [Related]  

  • 7. Reply to Francesco Montorsi, Giorgio Gandaglia, Nicola Fossati, Andrea Salonia, and Alberto Briganti's Letter to the Editor re: Vasilis Stavrinides, Francesco Giganti, Bruce Trock, et al. Five-year Outcomes of Magnetic Resonance Imaging-based Active Surveillance for Prostate Cancer: A Large Cohort Study. Eur Urol 2020;78:443-51.
    Stavrinides V; Giganti F; Emberton M; Moore CM
    Eur Urol; 2020 Oct; 78(4):e166. PubMed ID: 32712048
    [No Abstract]   [Full Text] [Related]  

  • 8. Reply to Erfan Ayubi and Saeid Safiri's Letter to the Editor re: R. Jeffrey Karnes, Voleak Choeurng, Ashley E. Ross, et al. Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2017.03.036. Methodological Issues.
    Trock BJ; Karnes RJ
    Eur Urol; 2017 Dec; 72(6):e158-e159. PubMed ID: 28576503
    [No Abstract]   [Full Text] [Related]  

  • 9. Re: Jeffrey J. Tosoian, Mufaddal Mamawala, Jonathan I. Epstein, et al. Active Surveillance of Grade Group 1 Prostate Cancer: Long-term Outcomes from a Large Prospective Cohort. Eur Urol 2020;77:675-82.
    Mai Z; Yuan R
    Eur Urol; 2020 Sep; 78(3):e133-e134. PubMed ID: 32444263
    [No Abstract]   [Full Text] [Related]  

  • 10. Re: Jeffrey J. Tosoian, Mufaddal Mamawala, Jonathon I. Epstein, et al. Active Surveillance of Grade Group 1 Prostate Cancer: Long-term Outcomes from a Large Prospective Cohort. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.12.017.
    Froehner M; Koch R; Thomas C
    Eur Urol; 2020 Aug; 78(2):e91. PubMed ID: 32381458
    [No Abstract]   [Full Text] [Related]  

  • 11. Re: Vasilis Stavrinides, Francesco Giganti, Bruce Trock, et al. Five-year Outcomes of Magnetic Resonance Imaging-based Active Surveillance for Prostate Cancer: A Large Cohort Study. Eur Urol 2020;78:443-51.
    Montorsi F; Gandaglia G; Fossati N; Salonia A; Briganti A
    Eur Urol; 2020 Oct; 78(4):e165. PubMed ID: 32798145
    [No Abstract]   [Full Text] [Related]  

  • 12. Re: Vasilis Stavrinides, Francesco Giganti, Bruce Trock, et al. Five-year Outcomes of Magnetic Resonance Imaging-based Active Surveillance for Prostate Cancer: A Large Cohort Study. Eur Urol 2020;78:443-51.
    Chu CE; Lonergan PE; Carroll PR
    Eur Urol; 2020 Sep; 78(3):e110-e111. PubMed ID: 32622551
    [No Abstract]   [Full Text] [Related]  

  • 13. Re: Simpa S. Salami, Jeffrey J. Tosoian, Srinivas Nallandhighal, et al. Serial Molecular Profiling of Low-grade Prostate Cancer to Assess Tumor Upgrading: A Longitudinal Cohort Study. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.06.041.
    Orczyk C; Marsden T; Emberton M
    Eur Urol; 2021 Mar; 79(3):e98-e99. PubMed ID: 33341284
    [No Abstract]   [Full Text] [Related]  

  • 14. Reply to Pim J. van Leeuwen and Henk G. van der Poel's Letter to the Editor re: Karim A. Touijer, Robert J. Karnes, Niccolo Passoni, et al. Survival Outcomes of Men with Lymph Node-positive Prostate Cancer After Radical Prostatectomy: A Comparative Analysis of Different Postoperative Management Strategies. Eur Urol 2018;73:890-6.
    Touijer K
    Eur Urol; 2018 Jul; 74(1):e18-e19. PubMed ID: 29691082
    [No Abstract]   [Full Text] [Related]  

  • 15. Reply to Erik Rud and Eduard Baco's Letter to the Editor re: Re: Jeffrey C. Weinreb, Jelle O. Barentsz, Peter L. Choyke, et al. PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2. Eur Urol 2016;69:16-40.
    Barentsz JO; Choyke PL; Cornud F; Haider MA; Macura KJ; Margolis D; Shtern F; Padhani AR; Tempany CM; Thoeny HC; Verma S; Weinreb JC
    Eur Urol; 2016 Nov; 70(5):e137-e138. PubMed ID: 27130148
    [No Abstract]   [Full Text] [Related]  

  • 16. Reply to Thomas Van den Broeck, R. Jeffrey Karnes, and Steven Joniau's Letter to the Editor re: Amar U. Kishan, Talha Shaikh, Pin-Chieh Wang, et al. Clinical Outcomes for Patients with Gleason Score 9-10 Prostate Adenocarcinoma Treated With Radiotherapy or Radical Prostatectomy: A Multi-institutional Comparative Analysis. Eur Urol 2017;71:766-73.
    Kishan AU; Steinberg ML; Kupelian PA; King CR
    Eur Urol; 2017 Nov; 72(5):e123-e124. PubMed ID: 28111115
    [No Abstract]   [Full Text] [Related]  

  • 17. Re: R. Jeffrey Karnes, Voleak Choeurng, Ashley E. Ross, et al. Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2017.03.036.
    Ayubi E; Safiri S
    Eur Urol; 2017 Dec; 72(6):e157. PubMed ID: 28576506
    [No Abstract]   [Full Text] [Related]  

  • 18. Reply to Christian Daniel Fankhauser, Lorelei A. Mucci, and Travis A. Gerke's Letter to the Editor re: Won Sik Ham, Heather J. Chalfin, Zhaoyong Feng, et al. New Prostate Cancer Grading System Predicts Long-term Survival Following Surgery for Gleason Score 8-10 Prostate Cancer. Eur Urol 2017;71:907-12.
    Epstein JI; Trock B; Han M
    Eur Urol; 2017 Jul; 72(1):e11-e12. PubMed ID: 28108147
    [No Abstract]   [Full Text] [Related]  

  • 19. Reply to Carsten Stephan, Henning Cammann, and Klaus Jung's Letter to the Editor re: Scott A. Tomlins, John R. Day, Robert J. Lonigro, et al. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.04.039.
    Tomlins SA; Groskopf J; Chinnaiyan AM
    Eur Urol; 2015 Nov; 68(5):e108. PubMed ID: 26242717
    [No Abstract]   [Full Text] [Related]  

  • 20. Reply to Satoshi Funada, Takashi Yoshioka, and Yan Luo's Letter to the Editor re: Lisa Moris, Marcus G. Cumberbatch, Thomas Van den Broeck, et al. Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review. Eur Urol 2020;77:614-27.
    Moris L; Van den Broeck T; Wiegel T;
    Eur Urol; 2020 Sep; 78(3):e120-e121. PubMed ID: 32684306
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.